Table 2 Effect of CurNPs and ZnONPs administration on fasting blood glucose, serum fasting insulin, HOMA-IR, HOMA-β, and AGEs levels of HFD/STZ-induced diabetic and control rats.

From: Ameliorative effect of curcumin and zinc oxide nanoparticles on multiple mechanisms in obese rats with induced type 2 diabetes

Groups

Fasting blood glucose (mg/dl)

Serum fasting insulin (µIU/ml)

HOMA-IR

HOMA-β

Serum AGEs (pg/ml)

Control

98.60 ± 1.03c

24.30 ± 0.10e

5.91 ± 0.06d

246.64 ± 8.0 h

11.33 ± 0.50d

HFD/STZ

481.00 ± 0.71a

180.44 ± 0.43a

214.30 ± 0.68a

155.40 ± 0.39i

26.21 ± 0.78a

HFD/STZ-Cur

109.20 ± 0.86b

80.44 ± 0.15b

21.68 ± 0.17b

627.66 ± 11.68 g

17.24 ± 0.51b,c

HFD/STZ-CurNPs-10

75.00 ± 0.71e

70.32 ± 0.20c

13.02 ± 0.10c

2140.85 ± 133.58b

13.26 ± 0.65d

HFD/STZ-CurNPs-50

79.80 ± 0.58d,e

78.60 ± 0.31b

15.48 ± 0.14c

1692.45 ± 58.52d

16.98 ± 0.37c

HFD/STZ- ZnSO4

76.60 ± 0.93e

66.99 ± 0.07d

12.67 ± 0.15c

1808.50 ± 128.84c

19.43 ± 0.45b

HFD/STZ-ZnONPs-10

98.00 ± 0.71c

81.70 ± 0.20b

19.76 ± 0.16b

841.70 ± 17.00f.

18.33 ± 0.37b

HFD/STZ-ZnONPs-50

83.00 ± 0.71d

77.96 ± 0.14b

15.97 ± 0.12c

1410.68 ± 51.42e

15.01 ± 0.74c

HFD/STZ-MT

74.00 ± 0.71e

71.26 ± 0.09c

13.02 ± 0.13c

2371.73 ± 154.84a

20.33 ± 0.42b

  1. Values are expressed as mean ± SEM (n = 7), means for the same parameter with different letters in each column are significantly different (Tukey, p < 0.01).